Increased visceral fat mass and insulin signaling in colitis-related colon carcinogenesis model mice

Author(s)
Miyamoto, Shingo; Tanaka, Takuji; Murakami, Akira

Citation
Chemico-Biological Interactions (2010), 183(2): 271-275

Issue Date
2010-01

URL
http://hdl.handle.net/2433/91255

Rights
© 2009 Elsevier Ireland Ltd. All rights reserved.; This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。

Type
Journal Article

Textversion
author

Kyoto University
Increased visceral fat mass and insulin signaling in colitis-related colon carcinogenesis model mice

Shingo Miyamoto\textsuperscript{a}, Takuji Tanaka\textsuperscript{b}, and Akira Murakami\textsuperscript{a,*}

\textsuperscript{a}Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan

\textsuperscript{b}Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan

\textsuperscript{*}Corresponding author. Fax: +81-75-753-6284; E-mail: cancer@kais.kyoto-u.ac.jp

Abbreviations: Akt, protein kinase B; AOM, azoxymethane; CD, Crohn’s disease; CRC, colorectal cancer; DSS, dextran sulfate sodium; ERK, extracellular signal-regulated protein kinase; IBD, inflammatory bowel disease; IL-6, interleukin-6; mTOR, mammalian target of rapamycin; Ob-R, leptin receptor; TNF-\(\alpha\), tumor necrosis factor-\(\alpha\)
Abstract

Leptin, a pleiotropic hormone regulating food intake and metabolism, plays an important role in the regulation of inflammation and immunity. We previously demonstrated that serum leptin levels are profoundly increased in mice which received azoxymethane (AOM) and dextran sulfate sodium (DSS) as tumor-initiator and -promoter, respectively, in a colon carcinogenesis model. In this study, we attempted to address underlying mechanism whereby leptin is up-regulated in this rodent model. Five-week-old male ICR mice were given a single intraperitoneal injection of AOM (week 0), followed by 1% DSS in drinking water for 7 days. Thereafter, the weights of visceral fats and the serum concentration of leptin were determined at week 20. Of interest, the relative epididymal fat pad and mesenteric fat weights, together with serum leptin levels in the AOM and/or DSS-treated mice were markedly increased compared to that in untreated mice. In addition, leptin protein production in epididymal fat pad with AOM/DSS-treated mice was 4.7-fold higher than that of control. Further, insulin signaling molecules, such as protein kinase B (Akt), S6, mitogen-activate protein kinase/ extracellular signaling-regulated kinase 1/2, and extracellular signaling-regulated kinase 1/2, were concomitantly activated in epididymal fat of AOM/DSS-treated mice. This treatment also increased the serum insulin and IGF-1 levels. Taken together, our results suggest that higher levels of serum insulin and IGF-1 promote the insulin signaling in epididymal fat and thereby increasing serum leptin, which may play an crucial role in, not only obesity-related, but also -independent colon carcinogenesis.

Key words: leptin, colon carcinogenesis, epididymal fat pad, insulin signaling
**Introduction**

Leptin, a 16-kDa protein encoded by the *ob* gene, was discovered in 1994 and shown to be a regulator of body weight and energy balance, functioning in the hypothalamus [1]. Although this hormone is produced mainly by WAT, its expression has also been detected in other tissues, including the gastrointestinal tract [2]. In humans, leptin levels are proportional to body mass index and are elevated in obese individuals [3]. Since obesity is known to increase the risk of certain cancers, great effort has been directed to elucidating the possible role of leptin in cancer development [4], and several *in vitro* studies showed that leptin can act as a mitogenic, anti-apoptotic, and tumorigenic factor with various cancer cell lines [5-7]. In addition, data obtained with clinical samples revealed that leptin and its receptor (Ob-R) are expressed in cancer tissues [8]. Thus, the leptin system might promote cancer progression in an autocrine and paracrine manner.

Our previous investigation demonstrated that serum leptin levels were profoundly increased in male ICR mice that received azoxymethane (AOM) and dextran sulfate sodium (DSS) for colitis-related colon carcinogenesis [9]. In addition, a citrus flavonoid, nobiletin, reduced not only those levels, but also colonic tumor development, whereas did not cause significant alterations in serum levels of other adipocytokines (TNF-α, IL-6, and adiponectin) and triglyceride [9]. These findings led us to address and investigate an issue why and how serum leptin level is elevated in the mice treated with AOM and DSS in a colitis-related colon carcinogenesis model.

**Materials and Methods**
Animals and chemicals

Male Crj:CD-1 (ICR) mice (Japan SLC, Shizuoka, Japan) aged 5 weeks were obtained for this study. The animals were handled according to the Guidelines for the Regulation of Animals provided by the Experimentation Committee of Kyoto University and the experimental protocol was approved by the Committee. Upon arrival, all mice were randomized and transferred to plastic cages (5 mice/cage), with free access to drinking water and a pelleted basal diet MF diet (Oriental Yeast, Kyoto, Japan), and controlled conditions of humidity (60 ± 5%), light (12/12-hour light/dark cycle) and temperature (24 ± 2°C). All mice were quarantined for 1 week before starting the experiments.

The colonic carcinogen AOM was purchased from Sigma Chemical Co. (St. Louis, MO). DSS with a molecular weight of 36,000 to 50,000 (Cat. No. 160110) was purchased from the MP Biochemicals, LLC (Aurora, OH) and used for induction of colitis, after being dissolved in distilled water to a concentration of 1% (w/v).

Antibodies

Antibodies directed against phospho-protein kinase B (Akt) (Ser483), phospho-S6 (Ser240/244), phospho-mitogen-activate protein kinase/ extracellular signaling-regulated kinase (MEK)1/2 (Ser217/221) and phospho- extracellular signaling-regulated kinase (ERK)1/2 (Thr202/Tyr204), as well as horseradish peroxidase (HRP)-conjugated anti-rabbit antibody were obtained from Cell Signaling Technology (Beverly, MA).
Animal treatment

A total of 80 male ICR mice were divided into four (3 experimental and 1 control) groups. Group 1 served as an untreated control. Mice in groups 2 and 4 were given a single i.p. injection of AOM (10 mg/kg body weight), then starting 1 week after that injection, those in group 4 received 1% DSS in drinking water for 7 days. Mice on group 3 received DSS alone according to the same time schedule. All groups were fed the basal diet throughout the study. At the end of weeks 2, 5 mice from each group were euthanized, then 15 mice from each group were euthanized after week 20. Euthanasia was performed under ether anesthesia, then blood samples were collected from the abdominal aorta. During the study, body weights of all animals were weighted weekly. At sacrifice, all organs, including adipose tissue, were removed and weighted, and then obtained adipose tissues were frozen using liquid nitrogen, until later use.

Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was extracted from the epididymal fat pads using TRIzol reagent (Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions. cDNA was synthesized using 1 µg of total RNA with an RNA PCR Kit (AMV). PCR amplification was performed using a thermal cycler (PTC-100TM, MJ Research, Watertown, MA) and conducted with each sense and antisense primer, with GAPDH used as the internal standard. The primers for leptin were 5’-CCAAAACCCTCATCAAGACC-3’ and 5’-GTCCAACTGTTGAAGAATGTCCC-3’ (Proligo, Kyoto, Japan), which yielded an expected band size of 395 bp, while those for GAPDH were 5’-GTGAAGGTCGGA-GTCAACG-3’ and 5’-GGTGAAGACGCCAGTGGACTC-3’ (Proligo), which yielded an expected band size of 300 bp. The primers were used at final concentrations of 0.5
and 0.05 µM respectively. PCR was performed under the following conditions: 43 cycles at 95ºC for 45 seconds, 57ºC for 45 seconds, and 72ºC for 45 seconds for leptin, and 27 cycles at 94ºC for 30 seconds, 55ºC for 30 seconds, and 72ºC for 30 seconds for GAPDH. The PCR products were subjected to electrophoresis on 3% agarose gels and stained with SYBR® Gold. The intensity of each band was analyzed using Scion Image.

Western blotting

To determine the protein expressions of phospho-Akt, phospho-S6, phospho-MEK1/2, and phospho-ERK1/2 in the epididymal fat pads, tissue supernatants were subjected to Western blotting. Frozen adipose tissue was lysed in lysis buffer [10 mM Tris, pH 7.4, 1% sodium dodecyl sulfate (SDS), 1 mM sodium metavanadate (V)], and centrifuged at 3200 x g for 5 minutes. Denatured proteins (40 µg) were separated using SDS-PAGE on a 10% polyacrylamide gel and then transferred to Immobilon-P membranes (Millipore, Billerica, MA). After blocking with Block Ace (Snow Brand Milk Products, Tokyo, Japan) for 1 hour, the membranes were reacted with the corresponding specific primary antibody (1:1000), followed by the corresponding HRP-conjugated secondary antibody (1:1000). The blots were developed using ECL Western blotting detection reagents. The intensity of each band was analyzed using Scion Image.

Clinical chemistry

The collected blood samples were used for clinical chemistry measurements of leptin (Quantikine Mouse leptin, ELISA/Assay Kit, R&D Systems Inc.), insulin (Insulin
measurement kit, Morinaga Institute of Biological Science), and insulin-like growth factor (IGF-1 (Quantikine Mouse IGF-1, ELISA/Assay Kit, R&D Systems Inc.). The samples were used without dilution for insulin measurements, while they were diluted 20- and 500-fold for leptin and IGF-1.

**Statistical analysis**

Data were analyzed using Student's *t*-test (two-sided) when appropriate, with *P* < 0.05 considered to indicate significance.

**Results**

**General observations of mice**

Food intake was significantly (*P* < 0.05) lower in group 4 as compared to group 1 (Figure 1A). The mean body weights of mice in groups 2 through 4 are higher than group 1, though the differences did not reach statistical significance (Figure 1B). In addition, the AOM and/or DSS treatment led to notable increases in mean relative epididymal fat pad weight (g/100 g body weight), which was most notable in group 4 (AOM and DSS), as the weight was significantly (*P* < 0.05) increased by 1.7-fold as compared to group 1 (Figure 1C). However, the mean relative mesenteric fat weight (g/100 g body weight) did not significantly differ among the groups (Figure 1D).

**Leptin level in the serum and epididymal fat pad**

As shown in Figure 2, the serum concentration of leptin in group 4 was significantly (*P* < 0.05) elevated by 3.0-fold as compared to group 1, which is consistent with our
previous findings [9]. The serum leptin levels in groups 2 and 3 were also increased by 1.8- and 2.2-fold as compared to group 1, respectively, without statistical significance. Since leptin is produced mainly by WAT, we assessed the level of leptin mRNA and protein expression in epididymal fat pads. Leptin mRNA expression in the mice treated with both AOM and DSS (group 4) was increased by 2.0-fold as compared to the untreated control (Figure 3A), while leptin protein production was also increased by 4.7-fold ($P < 0.05$) in group 4 mice (Figure 3B).

*Activation of insulin signaling pathway in epididymal fat pads*

Insulin is an important physiological factor that activates mammalian target of rapamycin (mTOR), which is a master regulator of protein synthesis [10], adipose tissue morphogenesis [11], and leptin synthesis/secretion [12] in adipocytes. To determine whether the insulin signaling pathway was activated in the epididymal fat pads of the present ICR mice, we determined the phosphorylation status of Akt, S6, MEK1/2, and ERK1/2, all of which are involved in that pathway [13]. As shown in Figure 3, AOM and DSS treatment substantially increased the phosphorylation of Akt (3.5-fold, $P < 0.05$, Figure 3C), S6 (38-fold, $P < 0.05$, Figure 3D), MEK (5.4-fold, $P < 0.05$, Figure 3E), and ERK (8.8-fold, $P < 0.05$, Figure 3F), respectively, as compared to the untreated control mice.

*Serum levels of insulin and IGF-1*

We also assessed the serum levels of insulin and IGF-1 at two time-points, week 2 (just after the cessation of the DSS treatment) and 20 (the termination of the study). As shown in Figure 4A, serum insulin was elevated in a time-dependent manner by 2.1-
and 7.8-fold in groups 1 and 4, respectively. Meanwhile, the level of IGF-1 in group 4 was significantly ($P < 0.05$) higher at week 20 than that in group 1, which was in contrast to the findings at week 2 (Figure 4B).

Discussion

Colorectal cancer (CRC) is the most serious complication associated with long standing inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease (CD) [14, 15]. Mesenteric WAT is mainly hypertrophic around the intestines in IBD patients, with axial polarity of inflammation the mainstay contributor [16]. To better understand the pathogenesis of IBD-related CRC, one (T.T.) of the present authors and colleagues developed a novel colitis-related CRC model (a two-stage mouse colon carcinogenesis model), which were initiated with AOM and promoted by DSS [17]. In the current study, such sequential treatment significantly increased serum leptin and epididymal fat pad weight, whereas mesenteric fat was not altered (Figure 1C and D). The individual potencies were less than their combination, suggesting that AOM and DSS act additively to increase the concentration of leptin in serum.

Bendet et al. reported that insulin secretion during a 3-hour oral glucose-tolerance test was increased and homeostatic model assessment values were decreased in CD patients [18]. In a later study, Bregenzer et al. found increased insulin resistance and $\beta$ cell function in CD patients [19]. Furthermore, it should be noted that the concentration of serum C-peptide, a stable indicator of steady-state insulin secretion, was reported to be higher in AOM-treated male rats [20]. Since insulin resistance increases the level of
serum IGF-1 [21], the increased level of IGF-1 in serum of the present group of mice (Figure 4B) may have been associated with putative insulin resistance caused by AOM/DSS-induced inflammation with other pathologic conditions, including oxidative stress.

Under physiological conditions, serum leptin levels are affected by several factors, and leptin secretion from adipocytes is dominantly dependent on the status of adipocyte signaling molecules. A previous study showed that both insulin and IGF-1 have been reported to be important physiological factors activating mTOR. Activation of this pathway mediates multiple insulin effects, such as stimulation of adipogenesis or lipogenesis [22], and potentiation of leptin secretion. In the present study, the insulin/IGF signaling pathway was consistently activated, and leptin induction and production were promoted in the epididymal fat of mice treated with AOM and DSS (Figure 3A-F). Thus, it is suggested that these hormones stimulate growth and differentiation of visceral fat tissue, thereby accelerating leptin production.

In conclusion, we found that higher levels of serum insulin and IGF-1 promote insulin signaling in epididymal fat, which may lead to increased amounts of visceral fat tissue and a resulting elevation of serum leptin. These events may play certain critical roles in the development of CRC. However, further studies are warranted for understanding the precise mechanisms underlying AOM and DSS-induced adipose tissue alterations.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Cancer Research from the
Ministry of Health, Labor and Welfare of Japan (A.M. and T.T.), a Grant-in Aid for Scientific Research (C) (A.M.), and the Japan Society for the Promotion of Science Fellows (S.M.).
References


[12] C. Roh, J. Han, A. Tzatsos, K. Kandror, Nutrient-sensing mTOR-mediated


Figure legends

Figure 1. The mean food intake (A) by the mice during the study, body (B), epididymal fat pad (C), and mesenteric fat (D) weights. The weights were measured at the end of the study.

Figure 2. Serum leptin levels of all groups. The levels were quantified by ELISA, as described in Materials and Methods. Each value is shown as the mean ± SD (n=15). Statistical analysis was performed using Student’s t-test: *P < 0.05 vs. the untreated control (group 1).

Figure 3. Leptin production and activation of insulin signaling pathway in epididymal fat pads at the end of the study. (A) Leptin mRNA expression was determined by RT-PCR, as described in Materials and Methods, with the levels corrected by those of GAPDH. Each value is shown as the mean ± SD (n=5), with 3 representative results presented. (B) Leptin protein amounts were quantified by ELISA, as described in Materials and Methods. Each value is shown as the mean ± SD (n=10). (C-F) Activation of the insulin signaling pathway was examined by Western blotting, as described in Materials and Methods. Each value is shown as the mean ± SD (n=10), with 3 representative results presented. Statistical analysis was performed using Student’s t-test: *P < 0.05 vs. the untreated control (group 1).

Figure 4. Levels of serum insulin (A) and IGF-1 (B) after weeks 2 and 20. Serum
insulin and IGF-1 levels were quantified by ELISA, as described in Materials and Methods. Open bars; at week 2, closed bars; at week 20. Each values is shown as the mean ± SD (n=5 or 15). Statistical analysis was performed using Student’s *t*-test: *P* < 0.05 vs. the untreated control (group 1) for the corresponding time point.
Fig. 1 (Miyamoto et al.)

A. **Body weight (g)**

B. **Epididymal fat pad weight (% body weight)**

C. **Mesenteric fat weight (% body weight)**

D. **Food intake (g/day)**

- **None**
- **AOM**
- **DSS**
- **AOM/DSS**
Fig. 2 (Miyamoto et al.)

Leptin (ng/ml)

None | AOM | DSS | AOM/DSS

*
Fig. 3 (Miyamoto et al.)

A. Leptin/GAPDH

B. Leptin/Protein (pg/mg)

C. pi-Akt/tubulin

D. pi-S6/tubulin

E. pi-MEK/tubulin

F. pi-ERK/tubulin
Fig. 4 (Miyamoto et al.)

A

Insulin (ng/ml)

None | AOM/DSS
---|---
0.5 | 1.5
1.0 | 3.0
1.5 | 4.5

B

IGF-1 (ng/ml)

None | AOM/DSS
---|---
0 | 100
100 | 200
200 | 300
300 | 400
400 | 500
500 | 600
600 | 700

*